Harmony Biosciences Holdings Inc
HRMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.83B
Close$
Share Statistics
| Market cap | $1.83 Billion |
|---|---|
| Enterprise Value | $1.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.76 |
| Beta | 0.97 |
| Outstanding Shares | 57,819,060 |
Return
| Return on Equity | 16.00% |
|---|---|
| Return on Assets | 11.45% |
| Return on Invested Capital | 19.00% |
Valuation & Multiples
| P/E Ratio | 12.54 |
|---|---|
| PEG | -43.72 |
| Price to Sales | 2.14 |
| Price to Book Ratio | 2.14 |
| Enterprise Value to Revenue | 1.4 |
| Enterprise Value to EBIT | 6.29 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$0.76
Average shareholder expectationRevenue Estimate
$220.84 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$0.87
Average shareholder expectationRevenue Estimate
$242.14 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.4154▲ 173.81% |
|---|---|
| Total Calls | 285,000▲ 0.28% |
| Total Puts | 688,400▲ 257.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 96.39%▲ 10.91% |
|---|---|
| Total Invested | $1.56B▼ 16.75% |
| Investors Holding | 317▼ 13.00% |
ESG Score
No data
About Harmony Biosciences Holdings Inc
150 employeesHarmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves patients in the United States.